Moreover, the 36-month beta value for COGT is 1.74. Analysts have varying opinions on the stock, with 2 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for COGT is 86.06M and currently, short sellers hold a 9.80% of that float. On November 13, 2024, COGT’s average trading volume was 1.03M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
COGT) stock’s latest price update
Cogent Biosciences Inc (NASDAQ: COGT)’s stock price has gone rise by 5.25 in comparison to its previous close of 10.38, however, the company has experienced a 4.25% increase in its stock price over the last five trading days. zacks.com reported 2024-06-28 that Cogent (COGT) announces a positive FDA meeting and alignment on MS2D2, a novel patient-reported outcome measure for the SUMMIT study. The company’s shares rise on the news.
COGT’s Market Performance
Cogent Biosciences Inc (COGT) has experienced a 4.25% rise in stock performance for the past week, with a -6.38% drop in the past month, and a 25.29% rise in the past quarter. The volatility ratio for the week is 5.38%, and the volatility levels for the past 30 days are at 6.48% for COGT. The simple moving average for the past 20 days is -3.89% for COGT’s stock, with a 25.75% simple moving average for the past 200 days.
Analysts’ Opinion of COGT
Many brokerage firms have already submitted their reports for COGT stocks, with Robert W. Baird repeating the rating for COGT by listing it as a “Neutral.” The predicted price for COGT in the upcoming period, according to Robert W. Baird is $8 based on the research report published on February 26, 2024 of the current year 2024.
Citigroup, on the other hand, stated in their research note that they expect to see COGT reach a price target of $11. The rating they have provided for COGT stocks is “Buy” according to the report published on February 08th, 2024.
Wedbush gave a rating of “Neutral” to COGT, setting the target price at $5 in the report published on December 11th of the previous year.
COGT Trading at -1.28% from the 50-Day Moving Average
After a stumble in the market that brought COGT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -13.36% of loss for the given period.
Volatility was left at 6.48%, however, over the last 30 days, the volatility rate increased by 5.38%, as shares sank -5.11% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -6.18% lower at present.
During the last 5 trading sessions, COGT rose by +2.77%, which changed the moving average for the period of 200-days by +143.12% in comparison to the 20-day moving average, which settled at $11.36. In addition, Cogent Biosciences Inc saw 85.80% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for COGT
Current profitability levels for the company are sitting at:
- -46.61 for the present operating margin
- 0.47 for the gross margin
The net margin for Cogent Biosciences Inc stands at -43.36. The total capital return value is set at -0.79. Equity return is now at value -66.55, with -65.53 for asset returns.
Based on Cogent Biosciences Inc (COGT), the company’s capital structure generated 0.05 points at debt to capital in total, while cash flow to debt ratio is standing at -10.73. The debt to equity ratio resting at 0.06. The interest coverage ratio of the stock is -56.01.
Currently, EBITDA for the company is -205.86 million with net debt to EBITDA at 0.31. When we switch over and look at the enterprise to sales, we see a ratio of 198.83. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.44.
Conclusion
To wrap up, the performance of Cogent Biosciences Inc (COGT) has been better in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
